Centre for Commercialization of Cancer Immunotherapy
VC Fund
Montréal, Canada
Centre for Commercialization of Cancer Immunotherapy is a VC fund in Montréal focused on Biotechnology and Health Care. Centre for Commercialization of Cancer Immunotherapy is to Accelerate the discovery, commercialization, and access to Cancer Immunotherapy.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Centre for Commercialization of Cancer Immunotherapy invests in
Stages Centre for Commercialization of Cancer Immunotherapy invests in
Countries Centre for Commercialization of Cancer Immunotherapy invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 2 (100%)
- Health Care 1 (50%)
- Life Science 1 (50%)
- Clinical Trials 1 (50%)
Stage
- Pre-Seed 1 (50%)
- Series A 1 (50%)
Country
- Canada 1 (50%)
- United States 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bobby Boursiquot
Vice President of Commercialization
|
Vice President of Commercialization | Total investments: 0 | Find email | |
Yvan Côté
President and CEO
|
President and CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Inspire Biotherapeutics
|
Inspire Biotherapeutics' objective is to create curative gene therapies for those suffering from lung ailments. | Pre-Seed / Mar 15, 2023 | |
Triumvira Immunologics
|
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cellreceptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer. | $55M / Series A / Aug 27, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Centre for Commercialization of Cancer Immunotherapy invest in?
Centre for Commercialization of Cancer Immunotherapy invests primarily in Biotechnology, Health Care and Life Science startups, most often at Pre-Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Centre for Commercialization of Cancer Immunotherapy?
Public channels for Centre for Commercialization of Cancer Immunotherapy include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Centre for Commercialization of Cancer Immunotherapy?
The team at Centre for Commercialization of Cancer Immunotherapy includes Bobby Boursiquot (Vice President of Commercialization) and Yvan Côté (President and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
